1256038-40-0 Usage
Uses
Used in Pharmaceutical Industry:
1-(5-Bromo-3-pyridinyl)cyclopropanecarboxylic acid is utilized as a therapeutic agent for neurological disorders due to its ability to modulate endocannabinoid signaling pathways, potentially leading to improved treatment outcomes for conditions such as anxiety, depression, and neurodegenerative diseases.
Additionally, it is used as an analgesic agent for pain management, leveraging its FAAH inhibitory properties to enhance the natural pain-relieving effects of endocannabinoids.
Furthermore, 1-(5-Bromo-3-pyridinyl)cyclopropanecarboxylic acid is employed as an anti-inflammatory agent, given its potential to reduce inflammation by interfering with the FAAH enzyme, which is implicated in inflammatory processes.
Lastly, it is used as an anticancer agent, with research indicating that 1-(5-Bromo-3-pyridinyl)cyclopropanecarboxylic acid may have the ability to inhibit the growth of cancer cells and potentially contribute to cancer treatment strategies by modulating the endocannabinoid system.
Check Digit Verification of cas no
The CAS Registry Mumber 1256038-40-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,6,0,3 and 8 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1256038-40:
(9*1)+(8*2)+(7*5)+(6*6)+(5*0)+(4*3)+(3*8)+(2*4)+(1*0)=140
140 % 10 = 0
So 1256038-40-0 is a valid CAS Registry Number.
1256038-40-0Relevant academic research and scientific papers
ALDOSTERONE SYNTHASE INHIBITORS
-
Page/Page column 102, (2012/11/13)
This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.
